Literature DB >> 19235841

Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination.

A Kyrka1, A Tragiannidis, D Cassimos, K Pantelaki, M Tzoufi, M Mavrokosta, X Pedeli, F Athanassiadou, A Hatzimichael, A Konstantopoulos, D Kafetzis, V Papaevangelou.   

Abstract

A national cross-sectional seroprevalence survey was conducted in order to evaluate the current seroepidemiology of hepatitis A among 1,383 children, aged 0-14 years, residing in Greece. Stratification of the study population was conducted according to age and area of residence. Sera from study participants were tested for the presence of anti-HAV IgG antibodies. Immigrant children, as well as children residing in rural areas, had lower immunization rates. Among unvaccinated children, the seroprevalence rate of anti-HAV was 17.1%. Nationality was shown to have a marginally significant effect since non-immunized immigrant children had a higher seroprevalence rate (22.4% vs. 15.9%, OR = 1.52, P = 0.064). Significant differences between geographic areas for both vaccination coverage and natural immunity were observed. The study findings indicate that hepatitis A is prevalent in Greece and therefore universal infant hepatitis A immunization should be implemented. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235841     DOI: 10.1002/jmv.21434

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Vaccination coverage among adolescents and risk factors associated with incomplete immunization.

Authors:  Irine-Ikbale Sakou; Artemis K Tsitsika; Vassiliki Papaevangelou; Eleni C Tzavela; Donald E Greydanus; Maria N Tsolia
Journal:  Eur J Pediatr       Date:  2011-04-05       Impact factor: 3.183

2.  Time trends in pediatric hospitalizations for hepatitis A in Greece (1999-2013): Assessment of the impact of universal infant immunization in 2008.

Authors:  V Papaevangelou; Z Alexopoulou; C Hadjichristodoulou; G Kourlamba; A Katsioulis; K Theodoridou; V Spoulou; M Theodoridou
Journal:  Hum Vaccin Immunother       Date:  2016-05-04       Impact factor: 3.452

3.  Molecular detection of multiple viral targets in untreated urban sewage from Greece.

Authors:  Petros A Kokkinos; Panos G Ziros; Aggeliki Mpalasopoulou; Alexis Galanis; Apostolos Vantarakis
Journal:  Virol J       Date:  2011-04-27       Impact factor: 4.099

4.  Molecular characterization of hepatitis A virus isolates from environmental and clinical samples in Greece.

Authors:  Petros Kokkinos; Panos Ziros; Sevasti Filippidou; Ioannis Mpampounakis; Apostolos Vantarakis
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

5.  Environmental surveillance. An additional/alternative approach for virological surveillance in Greece?

Authors:  Petros Kokkinos; Panos Ziros; Danai Meri; Sevasti Filippidou; Stella Kolla; Alexis Galanis; Apostolos Vantarakis
Journal:  Int J Environ Res Public Health       Date:  2011-06-01       Impact factor: 3.390

6.  Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks.

Authors:  Kassiani Mellou; Theologia Sideroglou; Vassiliki Papaevangelou; Anna Katsiaflaka; Nikolaos Bitsolas; Eleni Verykouki; Eleni Triantafillou; Agoritsa Baka; Theano Georgakopoulou; Christos Hadjichristodoulou
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

Review 7.  Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Authors:  Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

8.  Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review.

Authors:  Gustavo Hernandez-Suarez; Debasish Saha; Kris Lodroño; Phatu Boonmahittisut; Stephanus Taniwijaya; Ashwini Saha; Selim Badur; Yong Poovorawan
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.